AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has inaugurated its new corporate office in Mumbai, marking the next phase of growth through innovation, with a focus on expanding access to innovation, deepening partnerships, and addressing the country's most pressing healthcare needs.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has announced the voting results of its postal ballot, where two ordinary resolutions were passed with the requisite majority. The resolutions include the appointment of Mr. Arun Krishna as a Non-Executive Director and the change of designation of Ms. Bhavana Agrawal from Executive Director to Non-Executive Director.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has received an ESG rating of 73 for the financial year 2025-26 from NSE Sustainability Ratings and Analytics Limited.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has received a penalty order from the Registrar of Companies (ROC) for a delay in filing Form MR-2 related to the appointment of Dr. Sanjeev Kumar Panchal as Managing Director in 2023. The penalty is Rs. 1,88,000/- on the Company and Rs. 50,000/- each on the erstwhile concerned officers.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window will be closed from September 16, 2026, and will reopen after 48 hours from the declaration of Un-audited Financial Results of the Company for the quarter and half year ending September 30, 2026.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has informed the Exchange about the resignation of Dr. Sandeep Arora, Director – Medical Affairs, Biopharmaceutical Business Unit and Rare Disease Business Unit, effective close of business hours on September 15, 2026.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has informed the Exchange about General Updates, disclosing an ESG rating of 64 from Crisil ESG Ratings & Analytics Limited for fiscal year 2026.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has informed the Exchange about actions taken or orders passed regarding a demand notice issued by the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013. The Hon'ble High Court of Delhi has stayed the operation of the demand notice until the next date of hearing, subject to the Company depositing 15% of the amount mentioned in the demand notice.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has informed the Exchange about General Updates, specifically disclosing an ESG rating of 57 from Crisil ESG Ratings & Analytics Limited, based on publicly available information.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has informed the Exchange about a scheduled interaction with an institutional investor on August 26, 2026, via a virtual meeting.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has informed the Exchange about a scheduled interaction with analysts/investors on August 19, 2026, which may be subject to change.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on August 10, 2026, and informed the Exchange regarding voting results.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited reported a 30% growth in total revenue from operations to INR 6,828 Mn in Q1 FY2026–27, driven by continued momentum across its core therapy areas.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has held its 47th Annual General Meeting (AGM) on August 10, 2026, where it adopted financial statements, declared a dividend of Rs. 36 per equity share, and appointed new auditors and directors. The meeting was conducted through video conferencing, and remote e-voting was provided to members.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has submitted its financial results for the quarter ended June 30, 2026, reporting a 30% growth in total revenue from operations to INR 6,828 Mn in Q1 FY2026–27. The company's performance was driven by continued momentum across its core therapy areas—Oncology, Biopharmaceuticals (CVRM and R&I) and Rare Disease, reflecting the strength of its innovation-led strategy, disciplined execution and focus on improving patient outcomes in India.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization to import and sell Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu) for an additional indication in India.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013, amounting to Rs. 1,48,65,83,590, inclusive of interest calculated up to August 20, 2026. The company is evaluating the demand notice and appropriate legal actions.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013. The company is reviewing the notice and will take appropriate steps in accordance with applicable law.